Companies: 10,795·Total market cap: $144.5T
ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

ABVCNASDAQHealthcare● Active
$1.34
+$0.00(+0.29%)
Market Cap$19473708
P/E Ratio
52W High$5.48
52W Low$0.88
SEC Filings

ABVC BioPharma, Inc. (ABVC) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001173313 · ABVC · NASDAQ · as of Jun 9, 2026

Filing snapshot

780
Total Filings
10-Q
Latest Form
2026-05-18
Most Recent
2004
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001173313 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-03
Fiscal Year End
Mar 3, 2026
Accession No.
0001213900-26-023063
Primary Document
ea0278313-10k_abvcbio.htm
Source: data.sec.gov · CIK 0001173313 · Accession 0001213900-26-023063

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2026-05-18
8-KCurrent Report
CURRENT REPORT
2026-03-27Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
QUARTERLY REPORT
2026-05-18
View
NT 10-QNT 10-Q
NOTIFICATION OF LATE FILING
2026-05-15
View
POS AMPOS AM
POST-EFFECTIVE AMENDMENT NO. 5 TO FORM S-1
2026-03-27
View
8-KCurrent Report
CURRENT REPORT
2026-03-27
View
DEF 14AProxy Statement
DEFINITIVE PROXY STATEMENT
2026-03-05
View
10-KAnnual Report
ANNUAL REPORT
2026-03-03
View
10-Q/AQuarterly Report (Amended)
AMENDMENT NO. 1 TO FORM 10-Q
2026-03-03
View
8-KCurrent Report
CURRENT REPORT
2026-03-03
View
PRE 14APRE 14A
PRELIMINARY PROXY STATEMENT
2026-02-05
View
8-K/ACurrent Report (Amended)
AMENDMENT NO. 1 TO FORM 8-K
2026-01-16
View
424B4424B4
PROSPECTUS SUPPLEMENT
2025-11-14
View
424B4424B4
PROSPECTUS SUPPLEMENT
2025-11-14
View
424B4424B4
PROSPECTUS SUPPLEMENT
2025-11-14
View
424B4424B4
PROSPECTUS SUPPLEMENT
2025-11-14
View
8-KCurrent Report
CURRENT REPORT
2025-11-03
View
Showing 1–15 of 740 filingsForm 4 / 144 hidden· 780 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001173313  |  Exchange: NASDAQ · Healthcare

ABVC BioPharma, Inc. (NASDAQ: ABVC) has submitted 780 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2004. As a Healthcare sector company with CIK 0001173313, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is ABVC BioPharma, Inc.'s most comprehensive regulatory disclosure. The most recent ABVC BioPharma, Inc. 10-K was filed on 2026-03-03 for fiscal year ending 2026. Historical ABVC 10-K annual reports are available from 2002 through 2026.

Investors researching ABVC BioPharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ABVC SEC Filings · 8 questions

ABVC BioPharma, Inc. (ABVC) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 780 filings and access original documents at no cost. ABVC BioPharma, Inc.'s CIK is 0001173313.

ABVC SEC filingsABVC BioPharma, Inc. SEC documentsfind ABVC 10-K